Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Takeda Pharmaceutical ADR Rep 0.5 Ord Shs
TAK
Healthcare
Biotechnology
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
NYSE:TAK - Post by User
Takeda Pharmaceutical ADR Rep 0.5 Ord Shs
Bullboard Posts
Next >>
(1)
•••
SHFeatureArticl
X
Post by
SHFeatureArticl
on Feb 28, 2020 11:04am
425 Views
Post# 30746939
Healthcare Stocks to Watch
Healthcare Stocks to Watch
There is a wide array of offerings from innovative care to advanced digital technologies from every corner of the market assessing just about any patients’ needs, many of which have yet to be fully put into practice, which makes for an engaging “ground floor” investment opportunity.
Read more here ....
Bullboard Posts
Next >>
Draganfly sees Q3 growth, scores second major order from Fortune 50 telecom giant
After restructuring, Ballard Power Systems reports strong Q3 2025
Top US graphite deposit adds rare earth elements to the mix
CHAOS at DroneShield! OUT of Hensoldt? New price target for Almonty?
4 uranium price catalysts investors should know
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
SALT: quietly powering industries, keeping roads safe, and even shaping the global economy
The first public copper company permitted to drill in Argentina’s newly opened Mendoza province
Eshbal Signs Definitive Agreement to Acquire Majority Interest in NYC-Based Dare to Be Different Foods
Allied Critical Metals Confirms Ultra High-Grade Tungsten Zone at Borralha
Pinnacle Extends Gold-Silver Mineralized Horizon to Almost 500 Metres at Historic La Dura Mine